Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection vs Ozempic biosimilar comparison in type 2 diabetes
CTR20221251Phase 3Completed
- Sponsor
- Jiuyuan Gene Engineering
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), major adverse cardiac events (MACE), sponsored by Jiuyuan Gene Engineering. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)major adverse cardiac events (MACE)
Beyond the preview
Go deeper on CTR20221251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221251.